Coverage for Respiratory Panels (3-5 Targets)

  • Nov 9, 2020

Some good news for laboratories enrolled in the MOLDX program, passed along by Dustin Suntheimer, Vachette Pathology: As of October 1, 2020, the MOLDX program has updated its LCDs Billing and Coding Articles to cover Respiratory Panels billed by independent laboratories under CPT code 87631 (3-5 targets). See on the bottom of page 3 of the MOLDX Local Coverage Article, under "Coding Information...

Read


FDA Will No Longer Review EUA Submissions for SARS-CoV-2 Lab-Developed Tests

  • Nov 9, 2020

The US Food and Drug Administration announced it will no longer review SARS-CoV-2 Emergency Use Authorization submissions for lab-developed tests. In the latest of its weekly virtual town hall sessions, the agency asserted that the change is consistent with the recent statement by the US Department of Health and Human Services and will also help FDA prioritize the review process during the...

Read


HRSA Program Extended the Temporary Member ID - COVID-19 Claims Reimbursement

  • Nov 9, 2020

For professional and institutional outpatient – Temporary member ID will be valid for 90 days from date of service. Eligible claims can be submitted using the temporary member ID with date of service within the validity period. For example, if Patient A had a date of service of February 4, 2020, then the temporary ID assigned to her will be valid from February 4, 2020, through May 3, 2020....

Read


HHS Extends COVID-19 Related Public Health Emergency through January 20, 2021

  • Nov 9, 2020

On October 2, 2020, Health and Human Services (HHS) Secretary, Alex M. Azar II, announced the renewal of the public health emergency declaration due to the continued consequences of the COVID-19 pandemic. The 90-day renewal is effective October 23, 2020, and extends until January 20, 2021. The renewal impacts a number of regulatory flexibilities and temporary rules applicable to health...

Read


HHS Revises Reporting Requirements and Expands Relief Funding Eligibility

  • Nov 9, 2020

Department of Health & Human Services’ (HHS) October 22, 2020 press release, which updates existing relief fund reporting requirements and expands funding eligibility. As a result of negative feedback, HHS is amending the reporting instructions to increase flexibility as to how providers can apply relief funding to lost revenues attributable to coronavirus. Now, providers...

Read


Upcoming MIPS Important Dates and Deadlines

  • Nov 9, 2020

The Centers for Medicare & Medicaid Services (CMS) would like to remind clinicians of important upcoming Merit-based Incentive Payment System (MIPS) dates and deadlines: December 31 – 2020 Promoting Interoperability Hardship Exception and Extreme and Uncontrollable Circumstances Exception Applications Clinicians, groups, and virtual groups who believe they are eligible for these exceptions...

Read


Fourth COVID-19 Interim Final Rule with Comment Period (IFC-4) Price Transparency for COVID-19 Diagnostic Tests

  • Nov 9, 2020

Section 3202(b) of the CARES Act establishes a requirement for providers to publicize cash prices for COVID-19 diagnostic tests during the PHE. For purposes of implementing section 3202(b) of the CARES Act, this IFC adds a new 45 CFR part 182 to our regulations. This new requirement applies to every “provider of a COVID-19 diagnostic test” (or “provider”), which is defined as any facility that...

Read


Regence - Medicare Advantage Medical Policies - Changes Effective November 1, 2020

  • Nov 9, 2020

Genetic Testing Genetic and Molecular Diagnostics – Next Generation Sequencing and Genetic Panel Testing (Medicare #64) Reformatted policy by consolidating similar tests when reasonable to reduce the size of the policy, as well as the number of hyperlinks to manage Consolidated some columns to resize remaining columns with more detailed information Added the FoundationOne Liquid CDx (...

Read